Nanocarriers in Drug Delivery: Advancements, Clinical Applications, and Future Prospects

***Amol Mangal, [1]Gajendra Singh**

***Research Scholar, Shoolini University, Solan**

[1]Research Scholar, Shoolini University, Solan

Abstract: Nanocarriers have emerged as a transformative technology in the realm of drug delivery, offering the potential to revolutionize various therapeutic areas. This review provides a comprehensive overview of the current state and future prospects of nanocarriers in drug delivery, focusing on their role in enhancing patient compliance, overcoming physiological barriers, and targeted drug delivery. It also delves into the challenges and limitations that the field faces, such as oral bioavailability, disease-specific targeting, and material composition. The review concludes by highlighting the need for a multidisciplinary approach to overcome these challenges and fully realize the potential of nanocarriers in medicine.

Keywords: *Nanocarriers, Drug Delivery, Patient Compliance, Physiological Barriers, Targeted Delivery, Oral Bioavailability, Material Science, Multidisciplinary Approach.*

Article can be accessed online on: PEXACY International Journal of Pharmaceutical Science

Corresponding Author- amol.pharma2@gmail.com*

Update: Received on 01/02/2023; Accepted; 06/02/2023, Published on; 08/03/2023

Introduction

The pharmaceutical landscape has been undergoing a paradigm shift with the advent of nanotechnology, particularly in the realm of drug delivery systems. Nanocarriers have emerged as a revolutionary approach to address the limitations of traditional drug delivery systems, offering enhanced bioavailability, targeted delivery, and reduced side effects. This review aims to provide a comprehensive overview of the advancements in nanocarrier-based drug delivery systems, their clinical applications, and future prospects.

Advancements in Nanocarriers

Nanocarriers have seen significant advancements in recent years, particularly in the area of topical drug delivery. These advancements have been pivotal in overcoming the limitations of conventional formulations, such as poor penetration and low bioavailability ("Potential advancements of nanocarriers in topical drug delivery: a mini review," 2020). Surface modifications of lipid-based nanocarriers have also been explored as a potential approach to enhance targeted drug delivery (Priya et al., 2023).

Material Considerations

The choice of materials for constructing nanocarriers is crucial for their efficacy. Recent studies have focused on the assembly of polymers and liposomes for drug delivery, emphasizing the importance of surface modifications to create hybrid vesicles (De Leo et al., 2021). Carbon-based nanomaterials have also been investigated as versatile nanocarriers for drug delivery, showing promising results in terms of biocompatibility and drug loading capacity (Debnath & Srivastava, 2021).

Safety and Toxicity

As nanocarriers become more complex and multifunctional, concerns about their safety and toxicity have also risen. Recent studies have begun to explore the implications of multifunctional drug delivery nanocarriers on reproductive systems, both in vitro and in vivo (Ahmad, 2022).

Clinical Applications

Nanocarriers have found applications in various therapeutic areas, including tumor immunotherapy. Engineered multifunctional nanocarriers have been developed for controlled drug delivery in this context, showing promising results in preclinical studies (Katopodi et al., 2022). Lipid-based nanocarriers have also been investigated as topical drug delivery systems for intraocular diseases, offering potential benefits in terms of bioavailability and patient compliance (Navarro-Partida et al., 2021).

Future Prospects

The future of nanocarriers in drug delivery looks promising, with ongoing research focusing on the design of nucleic acid nanocarriers for controlled drug delivery (Mosley et al., 2023). However, challenges such as scalability, regulatory approval, and long-term safety studies remain to be addressed.

Regulatory Aspects of Nanocarriers in Drug Delivery

Regulatory Framework and Guidelines

The regulatory landscape for nanocarriers in drug delivery is complex and continuously evolving. Regulatory agencies such as the FDA and EMA have been working on establishing guidelines specific to nanocarriers, given their unique physicochemical properties and potential risks (Tewari et al., 2022). These guidelines aim to address the safety, efficacy, and quality of nanocarrier-based drug delivery systems, ensuring that they meet the required standards for clinical use.

Safety and Toxicity Evaluations

Safety and toxicity are paramount concerns in the regulatory approval of nanocarriers. Precision nanotoxicology has emerged as a vital area of research to understand the safety and toxicity implications of customized multifunctional nanocarriers for drug delivery applications (Ahmad et al., 2022). These studies are crucial for assessing the biocompatibility and potential adverse effects of nanocarriers, thereby informing regulatory decisions.

Clinical Trials and Approvals

Clinical trials for nanocarrier-based drug delivery systems are subject to rigorous regulatory scrutiny. Recent publications have discussed the regulatory aspects of clinical trials, patents, and future perspectives, particularly focusing on nose-to-brain drug delivery (Pandey et al., 2021). The translation from bench to clinic is often fraught with challenges, including the need for extensive preclinical and clinical data to support the safety and efficacy of these systems.

Pharmacoeconomic Considerations

The economic aspects of nanocarriers are also a significant concern from a regulatory standpoint. Current trends and challenges in the pharmacoeconomic aspects of nanocarriers have been discussed, emphasizing the need for cost-effective solutions that do not compromise on efficacy (Milewska et al., 2021).

Future Regulatory Challenges

As the field of nanocarriers continues to evolve, new regulatory challenges are likely to emerge. Fast-fed variability, molecular manifestations, and the overall regulatory aspects concerning drug delivery have been recently reviewed, highlighting the need for adaptive regulatory frameworks that can

accommodate the rapid advancements in this field (Rangaraj et al., 2022).

Environmental Impact of Nanocarriers in Drug Delivery

Ecological Footprint of Nanocarriers

The environmental impact of nanocarriers is an area of growing concern, especially considering the increasing use of these systems in drug delivery. The ecological footprint of nanocarriers is influenced by the materials used in their construction, the manufacturing processes, and their eventual degradation or disposal. Recent studies have begun to explore the environmental implications of nanocarriers, particularly those made from natural sources such as diatoms, which offer a more sustainable alternative (Maher et al., 2016).

Toxicological Concerns

The potential toxicity of nanocarriers to environmental organisms is another critical aspect that needs to be addressed. Studies have shown that engineered nanomaterials can have varying degrees of toxicity depending on their composition, size, and surface properties (Teow et al., 2011). Therefore, understanding the toxicological profile of nanocarriers is essential for assessing their environmental impact.

Biodegradability and Lifecycle Analysis

The biodegradability of nanocarriers is a crucial factor in determining their environmental impact. Lifecycle analyses of nanocarriers have been conducted to assess their overall environmental footprint, from raw material extraction to production, use, and disposal. Such analyses are vital for the development of more sustainable nanocarrier systems (Beckers et al., 2021).

Environmental Regulations and Guidelines

Environmental regulations specific to nanocarriers are still in their nascent stages. However, general guidelines for the environmental impact assessment of nanomaterials are being adapted to include nanocarriers. These guidelines aim to provide a framework for evaluating the environmental safety of nanocarrier-based drug delivery systems (Chandrakala et al., 2022).

Future Directions in Environmental Sustainability

As the field of nanocarriers continues to evolve, there is an increasing need for research focusing on their environmental sustainability. Innovative approaches are being explored to minimize the

environmental impact of nanocarriers, such as the use of biodegradable materials and green manufacturing processes (Wang et al., 2022).

Patient Compliance and Nanocarriers in Drug Delivery

Importance of Patient Compliance

Patient compliance is a critical factor in the success of any drug delivery system. Poor compliance can lead to suboptimal therapeutic outcomes and increased healthcare costs. Nanocarriers offer the potential to improve patient compliance through various mechanisms such as controlled release, targeted delivery, and reduced dosing frequency (Alqahtani et al., 2021).

Oral Drug Delivery and Compliance

Oral administration remains the most preferred route for drug delivery due to its convenience and non-invasiveness. However, the bioavailability of many drugs is compromised when administered orally. Polyaminoacid-based nanocarriers have shown promise in enhancing the bioavailability of orally administered drugs, thereby potentially improving patient compliance (Robla et al., 2020).

Overcoming Physiological Barriers

One of the significant challenges in drug delivery is overcoming physiological barriers such as the skin and the blood-brain barrier. Lipid-based nanocarriers have been studied for their potential to enhance the permeability of drugs across these barriers, thereby improving the efficacy of topical and central nervous system-targeted therapies (Khan et al., 2023).

Dermal Targeting for Skin Conditions

Skin conditions like psoriasis often require long-term treatment, which can be cumbersome for patients. Engineered nanocarriers have been developed for the dermal targeting of antipsoriatic drugs, offering a more effective and patient-friendly approach to managing this chronic condition (Tripathi et al., 2023).

CNS Drug Delivery

The central nervous system (CNS) is another challenging target for drug delivery due to the blood-brain barrier. Nanogels have emerged as a novel class of nanocarriers that can effectively deliver drugs to the CNS, thereby offering a new avenue for treating neurological disorders (Manimaran et al., 2023).

Asthma Management

In respiratory conditions like asthma, patient compliance is often compromised due to the complexity of inhaler devices or the frequency of medication. Nanocarriers have been explored for their potential to improve the delivery of asthma medications, thereby simplifying the treatment regimen (Ahmad, 2022).

Cancer Therapeutics

Oral drug delivery platforms based on nanocarriers are being developed for cancer treatment. These platforms aim to improve the bioavailability of anticancer drugs and reduce the frequency of administration, thereby enhancing patient compliance (Quadir et al., 2022).

Transdermal Drug Delivery

Transdermal patches based on nanostructured lipid carriers have been developed for sustained drug release, offering a convenient and non-invasive method of administration that can improve patient compliance (Hassan et al., 2022).

Osteoporosis Treatment

Nanotechnology is also being explored for targeted drug delivery in the treatment of osteoporosis. By improving the bioavailability and targeting of osteoporosis medications, nanocarriers can potentially enhance patient compliance in this long-term treatment (Kaur et al., 2023).

Future Prospects of Nanocarriers in Drug Delivery

Advancements in Topical Drug Delivery

The future of nanocarriers in drug delivery is promising, especially in the realm of topical applications for skin cancer. Advances in localized topical drug delivery systems are expected to provide more effective treatments with fewer side effects, thereby improving patient outcomes (Gupta et al., 2022).

Protein and Peptide Delivery

Lipid-based nanocarriers are gaining attention for the oral delivery of proteins and peptides. The challenges associated with the stability and bioavailability of these macromolecules are being addressed, opening up new avenues for oral administration of previously injectable-only medications (Naim et al., 2022).

Ocular Drug Delivery

Niosomal drug delivery systems are emerging as a viable option for treating ocular diseases. These systems offer the

advantage of enhanced bioavailability and prolonged retention time in the eye, making them a subject of intense research for future applications (Durak et al., 2020).

Multifunctional Therapeutic Nanocarriers

The development of multifunctional therapeutic hybrid nanocarriers is another exciting area of research. These systems are designed to offer targeted and triggered drug delivery, thereby increasing the therapeutic index and minimizing side effects (Kurtay et al., 2017).

Nanotechnology in Ophthalmology

Recent advances in nanotechnology-based ocular drug delivery systems are expected to revolutionize the treatment of eye diseases. These systems offer the potential for sustained release and targeted delivery, thereby improving the effectiveness of current therapies (Li et al., 2023).

Polymeric Micelles

Polymeric micelles have shown significant promise as nanocarriers for both drug and gene delivery. Their unique structure allows for the encapsulation of hydrophobic drugs, thereby improving their solubility and bioavailability (Nishiyama & Kataoka, 2006).

Arsenic Trioxide Delivery

Nanomedicine is also being explored for the delivery of arsenic trioxide to solid tumors. This approach aims to improve the therapeutic index of this potent anticancer agent, thereby making it a more viable option for cancer treatment (Sönksen et al., 2022).

Sugar-Based Polymers

The synthesis and biopharmaceutical applications of sugar-based polymers are an emerging area of research. These polymers offer the potential for biocompatibility and biodegradability, making them ideal candidates for future drug delivery systems (Wang et al., 2021).

Layered Double Hydroxides

Layered double hydroxides are another class of nanocarriers that are gaining attention. These materials offer the potential for high drug loading and controlled release, making them a subject of ongoing research (Bi et al., 2014).

Conclusion

Addressing the Multifaceted Challenges

The application of nanocarriers in drug delivery has shown immense promise, but it is not without its challenges. One of the primary concerns is the oral bioavailability of drugs delivered through lipid-based nanocarriers. While these carriers have shown potential in enhancing drug absorption, the variability in gastrointestinal conditions can significantly impact their effectiveness (Plaza-Oliver et al., 2021).

Targeting Specific Diseases

The use of nanocarriers for treating specific diseases like glioblastoma multiforme has been a subject of intense research. Tyrosine kinase inhibitors, for instance, have shown promise but face challenges in crossing the blood-brain barrier. Advanced nanocarrier systems are being developed to address this limitation (Brar et al., 2022).

Innovations in Material Science

The material composition of nanocarriers is another area undergoing rapid innovation. Photo-responsive polymeric nanocarriers are being developed for target-specific and controlled drug delivery, offering a new layer of precision in treatment modalities (Martín Giménez et al., 2021).

Copolymer-Based Nanocarriers

Recent advances in copolymer-based nanocarriers, particularly those involving PEO-PCL block and graft copolymers, have opened up new avenues for drug delivery applications. These materials offer unique properties that can be tailored for specific therapeutic needs (Chountoulesi et al., 2023).

Anticancer Drug Targeting

Nanocarriers have shown significant promise in anticancer drug targeting. However, the complexity of cancer biology presents challenges in achieving optimal drug delivery. Research is ongoing to understand these complexities better and to develop nanocarriers that can effectively target cancer cells (Dahiya et al., 2021).

Future Directions

The future of nanocarriers in drug delivery is bright but requires a multidisciplinary approach to overcome existing challenges. Innovations in material science, targeted drug delivery, and a better understanding of biological systems are essential for the successful application of nanocarriers in medicine (Wang et al., 2021).

References

1. Potential advancements of nanocarriers in topical drug delivery: a mini review." (2020). Letters in Applied Nanobioscience, 9(2), 968–974.

2. Priya, S., Desai, V. M., & Singhvi, G. (2023). Surface modification of lipid-based nanocarriers: A potential approach to enhance targeted drug delivery. ACS Omega, 8(1), 74–86.

3. De Leo, V., Milano, F., Agostiano, A., & Catucci, L. (2021). Recent advancements in polymer/liposome assembly for drug delivery: From surface modifications to hybrid vesicles. Polymers, 13(7), 1027.

4. Debnath, S. K., & Srivastava, R. (2021). Drug delivery with carbon-based nanomaterials as versatile nanocarriers: Progress and prospects. Frontiers in Nanotechnology, 3.

5. Ahmad, A. (2022). Safety and toxicity implications of multifunctional drug delivery nanocarriers on reproductive systems in vitro and in vivo. Frontiers in Toxicology, 4, 895667.

6. Katopodi, T., Petanidis, S., Tsavlis, D., Anestakis, D., Charalampidis, C., Chatziprodromidou, I., Eskitzis, P., Zarogoulidis, P., Kosmidis, C., Matthaios, D., & Porpodis, K. (2022). Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy. Frontiers in Oncology, 12, 1042125.

7. Navarro-Partida, J., Castro-Castaneda, C. R., Santa Cruz-Pavlovich, F. J., Aceves-Franco, L. A., Guy, T. O., & Santos, A. (2021). Lipid-based nanocarriers as topical drug delivery systems for intraocular diseases. Pharmaceutics, 13(5), 678.

8. Mosley, R. J., Rucci, B., & Byrne, M. E. (2023). Recent advancements in design of nucleic acid nanocarriers for controlled drug delivery. Journal of Materials Chemistry. B, Materials for Biology and Medicine, 11(10), 2078–2094.

9. Tewari, A. K., Upadhyay, S. C., Kumar, M., Pathak, K., Kaushik, D., Verma, R., Bhatt, S., Massoud, E. E. S., Rahman, M. H., & Cavalu, S. (2022). Insights on development aspects of polymeric nanocarriers: The translation from bench to clinic. Polymers, 14(17), 3545.

10. Ahmad, A., Imran, M., & Sharma, N. (2022). Precision nanotoxicology in drug development: Current trends and challenges in safety and toxicity implications of customized multifunctional nanocarriers for drug-delivery applications. Pharmaceutics, 14(11), 2463.

11. Pandey, A., Nikam, A., Basavraj, S., Mutalik, S., Gopalan, D., Kulkarni, S., Padya, B., Fernandes, G., & Mutalik, S. (2021). Nose-to-brain drug delivery: Regulatory aspects, clinical trials, patents, and future perspectives. In Direct Nose-to-Brain Drug Delivery (pp. 495–522). Elsevier.

12. Milewska, S., Niemirowicz-Laskowska, K., Siemiaszko, G., Nowicki, P., Wilczewska, A. Z., & Car, H. (2021). Current trends and challenges in pharmacoeconomic aspects of nanocarriers as drug delivery systems for cancer treatment. International Journal of Nanomedicine, 16, 6593–6644.

13. Rangaraj, N., Sampathi, S., Junnuthula, V., Kolimi, P., Mandati, P., Narala, S., Nyavanandi, D., & Dyawanapelly, S. (2022). Fast-fed variability: Insights into drug delivery, molecular manifestations, and regulatory aspects. Pharmaceutics, 14(9), 1807.

14. Maher, S., Kumeria, T., Wang, Y., Kaur, G., Fathalla, D., Fetih, G., Santos, A., Habib, F., Evdokiou, A., & Losic, D. (2016). From the mine to cancer therapy: Natural and biodegradable theranostic silicon nanocarriers from diatoms for sustained delivery of chemotherapeutics. Advanced Healthcare Materials, 5(20), 2667–2678.

15. Teow, Y., Asharani, P. V., Hande, M. P., & Valiyaveettil, S. (2011). Health impact and safety of engineered nanomaterials. Chemical Communications (Cambridge, England), 47(25), 7025–7038.

16. Beckers, S. J., Staal, A. H. J., Rosenauer, C., Srinivas, M., Landfester, K., & Wurm, F. R. (2021). Targeted drug delivery for sustainable crop protection: Transport and stability of polymeric nanocarriers in plants. Advanced Science (Weinheim, Baden-

Wurttemberg, Germany), 8(11), e2100067.

17. Chandrakala, V., Aruna, V., & Angajala, G. (2022). Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems. Emergent Materials, 5(6), 1593–1615.

18. Wang, S., Lv, Q., & Li, X. (2022). Recent advances in drug delivery nanocarriers for targeting hepatocellular carcinoma. Journal of Nanomaterials, 2022, 1–8.

19. Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021). Advances in oral drug delivery. Frontiers in Pharmacology, 12, 618411.

20. Robla, S., Alonso, M. J., & Csaba, N. S. (2020). Polyaminoacid-based nanocarriers: a review of the latest candidates for oral drug delivery. Expert Opinion on Drug Delivery, 17(8), 1081–1092.

21. Khan, M. S., Mohapatra, S., Gupta, V., Ali, A., Naseef, P. P., Kurunian, M. S., Alshadidi, A. A. F., Alam, M. S., Mirza, M. A., & Iqbal, Z. (2023). Potential of lipid-based nanocarriers against two major barriers to drug delivery-skin and blood-brain barrier. Membranes, 13(3).

22. Tripathi, D., Srivastava, M., Rathour, K., Rai, A. K., Wal, P., Sahoo, J., Tiwari, R. K., & Pandey, P. (2023). A promising approach of dermal targeting of antipsoriatic drugs via engineered nanocarriers drug delivery systems for tackling psoriasis. Drug Metabolism and Bioanalysis Letters.

23. Manimaran, V., Nivetha, R. P., Tamilanban, T., Narayanan, J., Vetriselvan, S., Fuloria, N. K., Chinni, S. V., Sekar, M., Fuloria, S., Wong, L. S., Biswas, A., Ramachawolran, G., & Selvaraj, S. (2023). Nanogels as novel drug nanocarriers for CNS drug delivery. Frontiers in Molecular Biosciences, 10, 1232109.

24. Ahmad, A. (2022). Pharmacological strategies and recent advancement in nano-drug delivery for targeting asthma. Life (Basel, Switzerland), 12(4), 596.

25. Quadir, S. S., Saharan, V., Choudhary, D., Harish, Jain, C. P., &

Joshi, G. (2022). Nano-strategies as oral drug delivery platforms for treatment of cancer: Challenges and future perspectives. AAPS PharmSciTech, 23(5), 152.

26. Hassan, D. H., Shohdy, J. N., El-Nabarawi, M., El-Setouhy, D. A., & Abdellatif, M. M. (2022). Nanostructured lipid carriers for transdermal drug delivery. International Journal of Applied Pharmaceutics, 88–93.

27. Kaur, M., Nagpal, M., & Aggarwal, G. (2023). Nanotechnology for targeted drug delivery to treat osteoporosis. Current Drug Targets, 24(1), 2–12.

28. Gupta, N., Gupta, G. D., & Singh, D. (2022). Localized topical drug delivery systems for skin cancer: Current approaches and future prospects. Frontiers in Nanotechnology, 4.

29. Naim, J., Sharmin, N., Shuma, M. L., & Halder, S. (2022). Lipid-based nanocarriers for oral delivery of proteins and peptides: Opportunities, challenges, and future prospects. Dhaka University Journal of Pharmaceutical Sciences, 395–416.

30. Durak, S., Esmaeili Rad, M., Alp Yetisgin, A., Eda Sutova, H., Kutlu, O., Cetinel, S., & Zarrabi, A. (2020). Niosomal drug delivery systems for ocular disease-recent advances and future prospects. Nanomaterials (Basel, Switzerland), 10(6), 1191.

31. Kurtay, G., Yılmaz, M., Kuralay, F., & Demirel, G. B. (2017). Multifunctional therapeutic hybrid nanocarriers for targeted and triggered drug delivery: recent trends and future prospects. In Nanostructures for Drug Delivery (pp. 461–493). Elsevier.

32. Li, S., Chen, L., & Fu, Y. (2023). Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. Journal of Nanobiotechnology, 21(1), 232.

33. Nishiyama, N., & Kataoka, K. (2006). Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacology & Therapeutics, 112(3), 630–648.

34. Sönksen, M., Kerl, K., & Bunzen, H. (2022). Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Medicinal Research Reviews, 42(1), 374–398.

35. Wang, J., Wang, D., Zhang, Y., & Dong, J. (2021). Synthesis and biopharmaceutical applications of sugar-based polymers: New advances and future prospects. ACS Biomaterials Science & Engineering, 7(3), 963–982.

36. Bi, X., Zhang, H., & Dou, L. (2014). Layered double hydroxide-based nanocarriers for drug delivery. Pharmaceutics, 6(2), 298–332.

37. Plaza-Oliver, M., Santander-Ortega, M. J., & Lozano, M. V. (2021). Current approaches in lipid-based nanocarriers for oral drug delivery. Drug Delivery and Translational Research, 11(2), 471–497.

38. Brar, H. K., Jose, J., Wu, Z., & Sharma, M. (2022). Tyrosine kinase inhibitors for glioblastoma multiforme: Challenges and opportunities for drug delivery. Pharmaceutics, 15(1), 59.

39. Martín Giménez, V. M., Arya, G., Zucchi, I. A., Galante, M. J., & Manucha, W. (2021). Photo-responsive polymeric nanocarriers for target-specific and controlled drug delivery. Soft Matter, 17(38), 8577–8584.

40. Chountoulesi, M., Selianitis, D., Pispas, S., & Pippa, N. (2023). Recent advances on PEO-PCL block and graft copolymers as nanocarriers for drug delivery applications. Materials, 16(6).

41. Dahiya, S., Dahiya, R., & Hernández, E. (2021). Nanocarriers for anticancer drug targeting: Recent trends and challenges. Critical Reviews in Therapeutic Drug Carrier Systems, 38(6), 49–103.

42. Wang, J., Gong, J., & Wei, Z. (2021). Strategies for liposome drug delivery systems to improve tumor treatment efficacy. AAPS PharmSciTech, 23(1), 27.